Skip to Content
Merck
CN
  • Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²⁺-dependent GABA type A receptor-mediated presynaptic modulation.

Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn²⁺-dependent GABA type A receptor-mediated presynaptic modulation.

The Journal of pharmacology and experimental therapeutics (2013-11-22)
Masahito Wakita, Naoki Kotani, Kyuya Kogure, Norio Akaike
ABSTRACT

Levetiracetam (LEV) is an antiepileptic drug with a unique but as yet not fully resolved mechanism of action. Therefore, by use of a simplified rat-isolated nerve-bouton preparation, we have investigated how LEV modulates glutamatergic transmission from mossy fiber terminals to hippocampal CA3 neurons. Action potential-evoked excitatory postsynaptic currents (eEPSCs) were recorded using a conventional whole-cell patch-clamp recording configuration in voltage-clamp mode. The antiepileptic drug phenytoin decreased glutamatergic eEPSCs in a concentration-dependent fashion by inhibiting voltage-dependent Na⁺ and Ca²⁺ channel currents. In contrast, LEV had no effect on eEPSCs or voltage-dependent Na⁺ or Ca²⁺ channel currents. Activation of presynaptic GABA type A (GABA(A)) receptors by muscimol induced presynaptic inhibition of eEPSCs, resulting from depolarization block. Low concentrations of Zn²⁺, which had no effect on eEPSCs, voltage-dependent Na⁺ or Ca²⁺ channel currents, or glutamate receptor-mediated whole cell currents, reduced the muscimol-induced presynaptic inhibition. LEV applied in the continuous presence of 1 µM muscimol and 1 µM Zn²⁺ reversed this Zn²⁺ modulation on eEPSCs. The antagonizing effect of LEV on Zn²⁺-induced presynaptic GABA(A) receptor inhibition was also observed with the Zn²⁺ chelators Ca-EDTA and RhodZin-3. Our results clearly show that LEV removes the Zn²⁺-induced suppression of GABA(A)-mediated presynaptic inhibition, resulting in a presynaptic decrease in glutamate-mediated excitatory transmission. Our results provide a novel mechanism by which LEV may inhibit neuronal activity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Piracetam
Sigma-Aldrich
Zinc, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.9%, granular
USP
Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Zinc, shot, <12 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Zinc, shot, 5 mm, 99.999% trace metals basis
Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard
Supelco
Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Zinc, foil, thickness 0.25 mm, 99.9% trace metals basis